Page last updated: 2024-12-05

selenocystine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Selenocystine is a non-proteinogenic amino acid containing selenium. It is a structural analog of cystine and is formed by the oxidation of selenocysteine. Selenocystine is a potent inhibitor of the enzyme glutathione reductase, which plays a role in reducing oxidative stress. It is also known to have antioxidant properties. Research on selenocystine focuses on its potential therapeutic applications in conditions such as cancer, inflammation, and neurological disorders. The unique properties of selenium in this compound contribute to its biological activity and make it an area of active investigation.'

selenocystine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15104
CHEBI ID28553
SCHEMBL ID160608
MeSH IDM0053742

Synonyms (33)

Synonym
ccris 3971
alanine, 3,3'-diselenodi-, dl-
dl-selenocystine
alanine, 3,3'-diselenobis-
d,l-selenocystine
seleno-dl-cystine
alanine, 3,3'-diselenodi-
selenium cystine
nsc172800
nsc-172800
selenocystine
seleno-dl-cystine, powder
1464-43-3
3,3'-diselenodialanine
CHEBI:28553
3,3'-diselane-1,2-diylbis(2-aminopropanoic acid)
3,3'-diselenobisalanine
AKOS000278328
n27t3b3mvn ,
2897-21-4
unii-n27t3b3mvn
selenocystine, dl-
SCHEMBL160608
selenocystin
AKOS024370386
JULROCUWKLNBSN-UHFFFAOYSA-N
DTXSID70862672
3,3'-diselenobis[alanine]
Q27103768
2-amino-3-(2-amino-2-carboxy-ethyl)selanylselanyl-propanoic acid
2-amino-3-[(2-amino-2-carboxyethyl)diselanyl]propanoic acid
(2r)-2-amino-3-[[(2r)-2-amino-2-carboxyethyl]diselanyl]propanoic acid
4-phenyl-2-(pyridin-3-yl)butanenitrile

Research Excerpts

Overview

Selenocystine (SeC) is a nutritionally available selenoamino acid presenting novel anticancer potential against human cancers.

ExcerptReferenceRelevance
"Selenocystine (SeC) is a nutritionally available selenoamino acid presenting novel anticancer potential against human cancers. "( Selenocystine inhibits JEG-3 cell growth
Fu, X; Hou, Y; Li, D; Sun, J; Wei, Z; Zhao, M, 2018
)
3.37
"Selenocystine (SeC) is a natural available selenoamino acid with novel anticancer efficacy."( Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling.
Chen, T; Fan, C; Fu, X; Li, X; Wong, YS; Zheng, W, 2014
)
1.34
"Selenocystine (SeC) is a nutritionally available selenoamino acid with selective anticancer effects on a number of human cancer cell lines. "( Selenocystine induces S-phase arrest and apoptosis in human breast adenocarcinoma MCF-7 cells by modulating ERK and Akt phosphorylation.
Chen, T; Wong, YS, 2008
)
3.23

Effects

Selenocystine (SeC) has been identified as a novel compound with broad-spectrum anticancer activity.

ExcerptReferenceRelevance
"Selenocystine (SeC) has been identified as a novel compound with broad-spectrum anticancer activity. "( Selenocystine induces oxidative-mediated DNA damage via impairing homologous recombination repair of DNA double-strand breaks in human hepatoma cells.
Chen, SC; Hsu, WL; Liang, HL; Luo, YH; Nien, CY; Wahyuni, EA; Wu, PY; Yang, SH; Yii, CY, 2022
)
3.61
"Selenocystine has been successfully identified in the former sample."( Simultaneous analysis of mercury and selenium species including chiral forms of selenomethionine in human urine and serum by HPLC column-switching coupled to ICP-MS.
García-Barrera, T; Gómez-Ariza, JL; Moreno, F, 2010
)
1.08

Toxicity

Methylseleninic acid, l-selenocystine, selenodiglutathione or selenite induced cell death in micromolar concentrations. Selenomethionine or ebselen was not toxic within the concentration range tested. Accumulation of the hydrogen selenide resulting from inhibition of the selenium methylation metabolism is found in animals following repeated administration of a toxic dose of selenocyStine.

ExcerptReferenceRelevance
" Accumulation of the hydrogen selenide resulting from inhibition of the selenium methylation metabolism, detoxification metabolic pathway of selenium, is found in animals following repeated administration of a toxic dose of selenocystine."( [Selenium methylation and toxicity mechanism of selenocystine].
Hasegawa, T; Nakamuro, K; Sayato, Y, 1997
)
0.74
" Methylseleninic acid, l-selenocystine, selenodiglutathione or selenite induced cell death in micromolar concentrations, whereas selenomethionine or ebselen was not toxic within the concentration range tested."( Comparison of different selenocompounds with respect to nutritional value vs. toxicity using liver cells in culture.
Birringer, M; Hoefig, CS; Köhrle, J; Renko, K; Schomburg, L, 2011
)
0.67
"Methyl mercury (MeHg) is a highly toxic substance and the effect of selenium against MeHg toxicity is a hot topic."( Selenocystine against methyl mercury cytotoxicity in HepG2 cells.
Chen, B; He, M; Hu, B; Wang, H; Yu, X, 2017
)
1.9

Bioavailability

We evaluated the effects of administration route and dose on the bioavailability of nine Se compounds found in biota. The triple-lumen perfusion method was used to measure the rate of absorption of trace quantities of selenium from the jejunum.

ExcerptReferenceRelevance
" In this study, the triple-lumen perfusion method was used to measure the rate of absorption of trace quantities of selenium (50 micrograms/liter in a physiological electrolyte solution) from the jejunum when given as D,L-selenomethione, D,L-selenocystine, or sodium selenite to healthy dogs in vivo."( Selenium absorption by canine jejunum.
Barbezat, GO; Reasbeck, PG; Robinson, MF; Thomson, CD; Weber, FL, 1985
)
0.45
"Various aspects of selenium metabolism and nutrition in relation to the question of selenium bioavailability in foods and the diet of man are reviewed."( Selenium bioavailability with reference to human nutrition.
Janghorbani, M; Nahapetian, A; Young, VR, 1982
)
0.26
"The objective of the present study was to describe the uptake and elimination kinetics of selenium (Se) administered in the forms of selenate, selenite, and selenomethionine (seleno-DL-methionine) in different life stages of the midge Chironomus dilutus, and to determine the relationship between Se bioavailability and Se speciation using X-ray absorption spectroscopy (XAS)."( Selenium bioaccumulation and speciation in Chironomus dilutus exposed to water-borne selenate, selenite, or seleno-DL-methionine.
Franz, ED; Janz, DM; Liber, K; Pickering, IJ; Wiramanaden, CI, 2011
)
0.37
"In vitro bioavailability of total selenium and selenium species from different raw seafood has been assessed by using a simulated gastric and intestinal digestion/dialysis method."( In vitro bioavailability of total selenium and selenium species from seafood.
Alonso-Rodríguez, E; Bermejo-Barrera, P; Domínguez-González, R; López-Mahía, P; Moreda-Piñeiro, A; Moreda-Piñeiro, J; Muniategui-Lorenzo, S; Prada-Rodríguez, D; Romarís-Hortas, V, 2013
)
0.39
" We evaluated the effects of administration route and dose on the bioavailability of nine Se compounds found in biota, the so-called bioselenocompounds, such as selenite, selenate, selenocyanate (SeCN), Se-methylselenocysteine (MeSeCys), selenomethionine (SeMet), selenohomolanthionine (SeHLan), selenocystine (SeCys2), 1β-methylseleno-N-acetyl-d-galactosamine (SeSug1), and trimethylselenonium ion (TMSe)."( Effect of administration route and dose on metabolism of nine bioselenocompounds.
Ogra, Y; Suzuki, N; Takahashi, K, 2018
)
0.66

Dosage Studied

ExcerptRelevanceReference
" Animals were dosed 6 days/week for 30, 60 or 90 days with 0, 5, 10 or 15 mg/kg per day."( Toxicity and chemical form of selenium in the liver of mice orally administered selenocystine for 90 days.
Hasegawa, T; Mihara, M; Nakamuro, K; Sayato, Y; Taniguchi, S, 1994
)
0.52
" In the present study, the toxicity of 4 compounds (selenate, selenite, methylselenocysteine, and selenocystine) to honeybee adult foragers and larvae was assessed using dose-response bioassays."( Effects of selenium on development, survival, and accumulation in the honeybee (Apis mellifera L.).
Hladun, KR; Kaftanoglu, O; Parker, DR; Tran, KD; Trumble, JT, 2013
)
0.61
"Radioresistance and limitation of irradiative dosage usually lead to failure in depletion of hypoxic tumors."( Dual-function nanosystem for synergetic cancer chemo-/radiotherapy through ROS-mediated signaling pathways.
Chen, T; He, L; Lai, H, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
selenoamino acid
diselenideCompounds having the structure RSe2R, with R =/= H.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Selenoamino Acid Metabolism1226

Research

Studies (161)

TimeframeStudies, This Drug (%)All Drugs %
pre-199029 (18.01)18.7374
1990's27 (16.77)18.2507
2000's32 (19.88)29.6817
2010's53 (32.92)24.3611
2020's20 (12.42)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.00 (24.57)
Research Supply Index5.09 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index42.91 (26.88)
Search Engine Supply Index2.07 (0.95)

This Compound (32.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (2.47%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other158 (97.53%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]